Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | Trastuzumab rezetecan |
Trade Name | |
Synonyms | SHR A1811|SHRA1811|SHR-A1811 |
Drug Descriptions |
Trastuzumab rezetecan (SHR-A1811) is an antibody-drug conjugate (ADC) comprising an ERBB2 (HER2)-targeting antibody linked to the camptothecin derivative rezetecan, which potentially induces DNA damage and apoptosis in ERBB2 (HER2)-expressing tumor cells and inhibits tumor growth (NCI Drug Dictionary, Cancer Res (2023) 83 (8_Supplement): LB031). |
DrugClasses | HER2 (ERBB2) Antibody 73 HER2 (ERBB2) Antibody-Drug Conjugate 27 |
CAS Registry Number | NA |
NCIT ID | C178312 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Trastuzumab rezetecan | Trastuzumab rezetecan | 0 | 1 |